| P2093 | author name string | F Roila | |
| | M Tonato | |
| | A Del Favero | |
| P2860 | cites work | Dexamethasone vs. placebo for cisplatin-induced emesis. A randomized cross-over trial | Q93642117 |
| | Pharmacological agents affecting emesis. A review (Part I) | Q28186636 |
| | Progress in the control of acute and delayed emesis induced by cisplatin | Q28326545 |
| | Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetr | Q33190512 |
| | Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron | Q33356839 |
| | Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin | Q34290044 |
| | Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? | Q35181690 |
| | Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis | Q35347118 |
| | The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin | Q35700794 |
| | Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret | Q35981578 |
| | The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial | Q36467992 |
| | Methodology of antiemetic trials: a review | Q37764625 |
| | Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide | Q40754288 |
| | Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial | Q41305280 |
| | Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy | Q41769603 |
| | Extrapyramidal reaction to ondansetron | Q42459199 |
| | Extrapyramidal reaction associated with ondansetron | Q42509531 |
| | Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting. | Q43024600 |
| | Ondansetron: confusing documentation surrounding an extrapyramidal reaction | Q43458680 |
| | Antiemetic efficacy of high-dose intravenous metoclopramide and dexamethasone in patients receiving cisplatin-based chemotherapy: a randomized controlled trial. | Q44429257 |
| | A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group | Q44495445 |
| | A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy | Q44559396 |
| | A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antiblastic agents. | Q44569388 |
| | Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial. | Q44620151 |
| | Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting | Q68447798 |
| | A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group | Q68478567 |
| | A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group | Q68478575 |
| | Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group | Q68478579 |
| | Methylprednisolone versus Metoclopramide for Prevention of Nausea and Vomiting in Breast Cancer Patients Treated with Intravenous Cyclophosphamide Methotrexate 5-Fluorouracil: A Double-Blind Randomized Study | Q68493429 |
| | Methylprednisolone in cis-platinum induced nausea and emesis: a placebo-controlled trial | Q68950854 |
| | Improved control of cisplatin-induced emesis with a combination of high doses of methylprednisolone and metoclopramide: a single-blind randomized trial | Q69056837 |
| | Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin | Q69291980 |
| | GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting | Q69299648 |
| | GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis | Q69300253 |
| | Randomized crossover antiemetic study in cisplatin-treated patients. Comparison between high-dose i.v. metoclopramide and high-dose i.v. dexamethasone | Q69485750 |
| | Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis | Q69716535 |
| | BRL 43694: a novel antiemetic to prevent nausea and vomiting induced by chemotherapy | Q69839197 |
| | Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy | Q70051225 |
| | The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting | Q70063203 |
| | Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study | Q70152930 |
| | Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting | Q70177918 |
| | Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy | Q70370019 |
| | Low-dose metoclopramide versus methylprednisolone in controlling chemotherapy induced nausea and vomiting | Q70417884 |
| | Cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting: a controlled study with high-dose metoclopramide | Q70813642 |
| | Extrapyramidal reactions with high-dose metoclopramide | Q71804122 |
| | Tropisetron and the 5-HT3 Antiemetics in Perspective. Proceedings of an international symposium. Vienna, Austria, October 2, 1992 | Q72230745 |
| | Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study | Q72884077 |
| | High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy | Q93605950 |
| | The use of methylprednisolone and metoclopramide in control of emesis in patients receiving cis-platinum | Q93608123 |
| | Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. | Q44886671 |
| | Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting | Q46207743 |
| | Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin | Q48949222 |
| | Methylprednisolone as an antiemetic drug. A randomised double blind study | Q49057183 |
| | Amitriptyline plus fluphenazine to prevent chemotherapy-induced emesis in cancer patients: a double-blind randomized cross-over study | Q49069510 |
| | Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. | Q51219038 |
| | Adjuvant propofol for refractory cisplatin-associated nausea and vomiting | Q51683398 |
| | Subhypnotic doses of propofol possess direct antiemetic properties | Q51693584 |
| | A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial | Q51701002 |
| | Double-blind crossover trial of single vs. divided dose of metoclopramide in a combined regimen for treatment of cisplatin-induced emesis | Q51720893 |
| | Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Re | Q51746449 |
| | Comparison of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapy. | Q51752029 |
| | Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. | Q51831525 |
| | Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. | Q52612776 |
| | A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group. | Q53405351 |
| | Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. | Q53708801 |
| | Randomized open cross-over trial between Metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting | Q53730507 |
| | Antiemetic efficacy of high-dose dexamethasone versus placebo in patients receiving cisplatin-based chemotherapy: a randomized double-blind controlled clinical trial. | Q53745789 |
| | Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. | Q53768861 |
| | Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. | Q54049124 |
| | Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. | Q54168667 |
| | Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. | Q55054035 |
| | Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics. | Q55420286 |
| | Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy | Q61868395 |
| | ONDANSETRON WITH AND WITHOUT DEXAMETHASONE TO TREAT CHEMOTHERAPY-INDUCED EMESIS | Q61868401 |
| | Effective Control of CMF-Related Emesis with High-Dose Dexamethasone | Q61900657 |
| | A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5-day cytostatic therapy | Q67491832 |
| | Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: comparison of placebo vs. adrenocorticotropic hormone (ACTH) | Q67493989 |
| | Prevention of cisplatin-induced emesis. The Italian Group for Antiemetic Research | Q67521991 |
| | Ondansetron and chest pain | Q67522201 |
| | Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy | Q67573467 |
| | Serotonin antagonist antiemetics: progress and concerns | Q67592410 |
| | Ondansetron is not associated with vascular adverse events, thrombocytopenia or renal failure | Q67592423 |
| | Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting | Q67594859 |
| | Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy | Q67697225 |
| | Acute and Delayed Emesis after Cisplatin-Based Regimen: Description and Prevention | Q67767819 |
| | Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research | Q67883137 |
| | A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy | Q67898658 |
| | Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy | Q67899919 |
| | Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone | Q67900841 |
| | Ondansetron (GR 38032F): a novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapy | Q67901472 |
| | Oral treatment with ondansetron in an outpatient setting | Q67902077 |
| | Extrapyramidal reaction caused by ondansetron | Q67903312 |
| | A randomized trial of high dose bolus metoclopramide versus low-dose continuous infusion metoclopramide in the prevention of cisplatin-induced emesis | Q68159292 |
| | High-dose oral and intravenous metoclopramide in doxorubicin/cyclophosphamide-induced emesis. A randomized double-blind study | Q68159297 |
| | Methylprednisolone for the control of CMF-induced emesis | Q68159301 |
| | Superiority of Granisetron to Dexamethasone Plus Prochlorperazine in the Prevention of Chemotherapy-Induced Emesis | Q68252503 |
| | Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy | Q68412436 |
| | Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis | Q68435561 |
| P433 | issue | 6 | |
| P304 | page(s) | 410-428 | |
| P577 | publication date | 1993-12-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities | |
| P478 | volume | 9 | |